Orgenesis Inc (ORGS) 0.6848 $ORGS
Scott Carmer Named as CEO of Orgenesis North America
Marketwire - Mon Aug 04, 8:03AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine, today announced the appointment of industry veteran Scott Carmer as CEO of the company's North American subsidiary. Carmer has more than 25 years of diverse industry experience within both pharmaceutical and biotech companies.
Orgenesis Signs Agreement With MaSTherCell to Scale Manufacturing of Insulin-Producing Liver Cells to Combat Diabetes
Marketwire - Mon Jul 07, 7:40AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine today announced that its Belgian subsidiary, Orgenesis SPRL, has signed a strategic agreement with MaSTherCell SA of Gosselies, Belgium. Orgenesis believes that the agreement will enable Orgenesis to advance its manufacturing (GMP) process from lab scale to clinical scale as it prepares for Phase I and Phase II clinical trials.
Orgenesis Receives $1.5 Million Term Loan to Help Fund Breakthrough Innovation in Diabetes Research
Marketwire - Wed Jun 25, 7:31AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine, announced today that it raised $1.5 million via a senior secured term loan facility.
Orgenesis to Present at the 2013 Gateway Conference on September 10
Marketwire - Wed Sep 04, 4:16PM CDT
Orgenesis, Inc. (OTCBB: ORGS), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, has been invited to present at the 2013 Gateway Conference being held on Tuesday, September 10, 2013 at the Palace Hotel in San Francisco.
Dr. David Sidransky Appointed to Orgenesis' Board of Directors
GlobeNewswire - Thu Jul 18, 1:00PM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"
, a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce the appointment of Dr. David Sidransky, Professor and Director of the Head and Neck Cancer Research Division at the Johns Hopkins University School of Medicine's Department of Otolaryngology, to its Board of Directors.
Orgenesis to Present Updates at Two Key June Conferences
GlobeNewswire - Thu May 30, 1:30PM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company" , a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce that it will be presenting updates on the Company's business and technology at two key conferences in the month of June.
Orgenesis and ATMI Enter Into Process Development Agreement
GlobeNewswire - Thu May 09, 6:55AM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company" , a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that its wholly owned subsidiary, Orgenesis Ltd., has entered into a process development agreement (the "PD Agreement" with ATMI, Inc. (Nasdaq:ATMI), a global technology company and leader in single-use bioprocess solutions.
Leading Diabetes Expert, Jay S. Skyler, M.D., Joins Orgenesis' Scientific Advisory Board
GlobeNewswire - Thu Apr 11, 7:15AM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company" , a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce the appointment of Jay S. Skyler, M.D., to its Scientific Advisory Board.
Orgenesis to Present at ATTD 2013
GlobeNewswire - Wed Feb 20, 1:11PM CST
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company" , a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce that its Chief Science Officer, Prof. Sarah Ferber, is scheduled to present at the 6 International Conference on Advanced Technologies & Treatments for Diabetes, to be held February 27 - March 3, 2013 in Paris, France.
Orgenesis Announces Management Changes
GlobeNewswire - Mon Jan 07, 7:00AM CST
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company" , a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today the appointment of Sav DiPasquale as President and Chief Executive Officer. Mr. DiPasquale succeeds Jacob BenArie, who has been appointed Chief Executive Officer of the Company's private subsidiary, Orgenesis Ltd.
Scott Carmer Named as CEO of Orgenesis North America
Marketwire - Mon Aug 04, 8:03AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine, today announced the appointment of industry veteran Scott Carmer as CEO of the company's North American subsidiary. Carmer has more than 25 years of diverse industry experience within both pharmaceutical and biotech companies.
Orgenesis Signs Agreement With MaSTherCell to Scale Manufacturing of Insulin-Producing Liver Cells to Combat Diabetes
Marketwire - Mon Jul 07, 7:40AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine today announced that its Belgian subsidiary, Orgenesis SPRL, has signed a strategic agreement with MaSTherCell SA of Gosselies, Belgium. Orgenesis believes that the agreement will enable Orgenesis to advance its manufacturing (GMP) process from lab scale to clinical scale as it prepares for Phase I and Phase II clinical trials.
Orgenesis Receives $1.5 Million Term Loan to Help Fund Breakthrough Innovation in Diabetes Research
Marketwire - Wed Jun 25, 7:31AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine, announced today that it raised $1.5 million via a senior secured term loan facility.
Orgenesis to Present at the 2013 Gateway Conference on September 10
Marketwire - Wed Sep 04, 4:16PM CDT
Orgenesis, Inc. (OTCBB: ORGS), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, has been invited to present at the 2013 Gateway Conference being held on Tuesday, September 10, 2013 at the Palace Hotel in San Francisco.
Dr. David Sidransky Appointed to Orgenesis' Board of Directors
GlobeNewswire - Thu Jul 18, 1:00PM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"
, a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce the appointment of Dr. David Sidransky, Professor and Director of the Head and Neck Cancer Research Division at the Johns Hopkins University School of Medicine's Department of Otolaryngology, to its Board of Directors. Orgenesis to Present Updates at Two Key June Conferences
GlobeNewswire - Thu May 30, 1:30PM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"
, a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce that it will be presenting updates on the Company's business and technology at two key conferences in the month of June. Orgenesis and ATMI Enter Into Process Development Agreement
GlobeNewswire - Thu May 09, 6:55AM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"
, a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that its wholly owned subsidiary, Orgenesis Ltd., has entered into a process development agreement (the "PD Agreement" with ATMI, Inc. (Nasdaq:ATMI), a global technology company and leader in single-use bioprocess solutions. Leading Diabetes Expert, Jay S. Skyler, M.D., Joins Orgenesis' Scientific Advisory Board
GlobeNewswire - Thu Apr 11, 7:15AM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"
, a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce the appointment of Jay S. Skyler, M.D., to its Scientific Advisory Board. Orgenesis to Present at ATTD 2013
GlobeNewswire - Wed Feb 20, 1:11PM CST
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"
, a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce that its Chief Science Officer, Prof. Sarah Ferber, is scheduled to present at the 6 International Conference on Advanced Technologies & Treatments for Diabetes, to be held February 27 - March 3, 2013 in Paris, France. Orgenesis Announces Management Changes
GlobeNewswire - Mon Jan 07, 7:00AM CST
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"
, a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today the appointment of Sav DiPasquale as President and Chief Executive Officer. Mr. DiPasquale succeeds Jacob BenArie, who has been appointed Chief Executive Officer of the Company's private subsidiary, Orgenesis Ltd. 
